Prediction of Response to Hormone Therapy in Prostate Cancer by Bromodeoxyuridine Labeling

预测癌症药物治疗的疗效，如前列腺癌的激素治疗或膀胱癌或肾癌的化疗，是非常有益的。在泌尿系统恶性肿瘤治疗前后，测定了细胞中DNA合成标志物溴脱氧尿苷（BrdU）的标记指数。为此，我们开发了一种用BrdU标记组织的新装置。该装置由一个注射器和一个容器组成，使得在体外对组织进行标记比以前更容易、更迅速。13例前列腺癌，10例膀胱癌，2例肾癌。在所有前列腺癌患者中，激素治疗后标记指数明显下降。4名患者显示标记指数大于2%，尽管其他许多患者没有显示标记细胞。4例患者中有3例出现疾病进展或早期复发。另一方面，没有标记细胞的患者没有复发或进展。在膀胱癌或肾癌方面没有明显的发现，因为这个系列的病例数量非常有限。

It is very beneficial to predict the efficacy of medical treatments for cancer such as the hormone treatment for prostate cancer or the chemotherapy for bladder or renal cancer. The labeling index of bromodeoxyuridine (BrdU), which is a marker of DNA synthesis in cells, was measured both before and after the treatment in tissues of urological malignancies. For this purpose we developed a new device for labeling tissues with BrdU. The device, composed of a syringe and a container, made it possible to labeling the tissue in vitro easier and more promptly than before. Thirteen patients with prostate cancer, 10 with bladder cancer and 2 with renal cancer were examined. In all the prostate cancer patients, the labeling index was much decreased after the hormone treatment. Four patients showed the labeling indexes greater than 2 per cents although many of others showed no labeled cells. Three of the 4 patients encountered progression or early relapse of the disease. On the other hand, patients with no labeling cells had no recurrence or progression.There were no significant findings on bladder cancer or renal cancer because the number of cases in this series was very limited.